Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TuHURA Biosciences ( (HURA) ) has provided an update.
On April 21, 2026, TuHURA Biosciences, Inc. entered into a secured loan agreement with Parkview Holdings One LLC, an affiliate of its largest shareholder, establishing a revolving credit facility of up to $50 million maturing on April 21, 2031 at a 12% annual interest rate. The facility allows monthly draws tied to TuHURA’s expense budget and is expected to extend the company’s cash runway into early 2028 while funding ongoing clinical trials and development programs, including its Phase 3 IFx-2.0 program and TBS-2025.
As part of the transaction, TuHURA agreed to a $5 million commitment fee payable in stock subject to shareholder approval, an annual 1.5% facility fee, profit-based principal repayments once product sales generate consecutive quarterly net profits, and restrictive covenants on additional debt, investments, and certain corporate actions. The company also amended warrants held by the shareholder affiliate to extend their exercise period to 2031 and granted Parkview a low to mid-single digit royalty on future net sales of IFx-2.0–based products, reinforcing insider backing but adding leverage, asset liens, and royalty obligations that will shape the economics of any future commercialization.
The most recent analyst rating on (HURA) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Neutral.
The score is held down primarily by weak financial fundamentals—no revenue, widening losses, and sharply worsening operating cash flow—implying continued reliance on financing. Technicals are a relative positive with price trending above major moving averages, but momentum is stretched (high RSI/Stoch). Corporate-event risk is elevated due to the Nasdaq minimum bid price notice, while valuation is difficult to support given negative earnings and no indicated dividend yield.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company developing novel therapeutics to overcome primary and acquired resistance to cancer immunotherapy in patients with advanced cancers. Its lead innate immune agonist IFx-2.0 is in a randomized Phase 3 registration trial as an adjunct to Keytruda for first-line treatment of advanced or metastatic Merkel cell carcinoma.
The company’s pipeline also includes TBS-2025, a VISTA-inhibiting monoclonal antibody moving into Phase 1b/2 development in mutNPM1 relapsed/refractory AML, and Delta Opioid Receptor-based bi-specific ADCs targeting myeloid-derived suppressor cells. TuHURA is listed on Nasdaq under the ticker HURA and focuses on addressing resistance mechanisms that limit the durability and efficacy of checkpoint inhibitors and cellular therapies.
Average Trading Volume: 1,954,375
Technical Sentiment Signal: Sell
Current Market Cap: $179.9M
See more insights into HURA stock on TipRanks’ Stock Analysis page.